XBiotech Statistics
Total Valuation
XBiotech has a market cap or net worth of $80.49 million. The enterprise value is -$67.34 million.
Important Dates
The next estimated earnings date is Tuesday, March 17, 2026, after market close.
| Earnings Date | Mar 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XBiotech has 30.49 million shares outstanding. The number of shares has increased by 0.09% in one year.
| Current Share Class | 30.49M |
| Shares Outstanding | 30.49M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 37.38% |
| Owned by Institutions (%) | 9.84% |
| Float | 19.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.49 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 41.78
| Current Ratio | 41.78 |
| Quick Ratio | 41.48 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -118.76 |
Financial Efficiency
Return on equity (ROE) is -16.23% and return on invested capital (ROIC) is -174.09%.
| Return on Equity (ROE) | -16.23% |
| Return on Assets (ROA) | -11.34% |
| Return on Invested Capital (ROIC) | -174.09% |
| Return on Capital Employed (ROCE) | -20.54% |
| Weighted Average Cost of Capital (WACC) | 8.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$331,318 |
| Employee Count | 88 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, XBiotech has paid $118,000 in taxes.
| Income Tax | 118,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.47% in the last 52 weeks. The beta is 0.80, so XBiotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | -27.47% |
| 50-Day Moving Average | 2.47 |
| 200-Day Moving Average | 2.75 |
| Relative Strength Index (RSI) | 55.81 |
| Average Volume (20 Days) | 48,606 |
Short Selling Information
The latest short interest is 100,114, so 0.33% of the outstanding shares have been sold short.
| Short Interest | 100,114 |
| Short Previous Month | 108,303 |
| Short % of Shares Out | 0.33% |
| Short % of Float | 0.52% |
| Short Ratio (days to cover) | 1.68 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -34.68M |
| Pretax Income | -29.04M |
| Net Income | -29.16M |
| EBITDA | -32.93M |
| EBIT | -34.68M |
| Earnings Per Share (EPS) | -$0.96 |
Full Income StatementBalance Sheet
The company has $147.37 million in cash and n/a in debt, with a net cash position of $147.37 million or $4.83 per share.
| Cash & Cash Equivalents | 147.37M |
| Total Debt | n/a |
| Net Cash | 147.37M |
| Net Cash Per Share | $4.83 |
| Equity (Book Value) | 167.08M |
| Book Value Per Share | 5.48 |
| Working Capital | 145.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$23.51 million and capital expenditures -$339,000, giving a free cash flow of -$23.85 million.
| Operating Cash Flow | -23.51M |
| Capital Expenditures | -339,000 |
| Free Cash Flow | -23.85M |
| FCF Per Share | -$0.78 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
